Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Jupiter Neurosciences (NASDAQ: JUNS) has announced NBA Hall of Famer Chris Webber as the second brand ambassador for their Nugevia™ longevity supplement line. The five-time NBA All-Star will promote the company's science-backed supplements built on the JOTROL™ platform, a patented resveratrol-based micellar delivery system.
The product line features three formulations - GLO, MND, and PWR - designed to enhance cellular resilience through synergistic ingredients optimized for absorption. This consumer initiative is part of Jupiter's dual-path strategy, targeting the $8 trillion longevity market by 2030 while supporting their clinical development programs and operational costs.
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato la leggenda della NBA e membro della Hall of Fame Chris Webber come secondo ambasciatore del marchio per la linea di integratori per la longevità Nugevia™. La star a cinque volte All-Star promuoverà gli integratori basati su evidenze scientifiche sviluppati sulla piattaforma JOTROL™, un sistema micellare brevettato a base di resveratrolo.
La gamma comprende tre formulazioni — GLO, MND e PWR — studiate per migliorare la resilienza cellulare tramite ingredienti sinergici ottimizzati per l’assorbimento. Questa iniziativa consumer rientra nella strategia a doppio binario di Jupiter, volta a raggiungere il mercato della longevità da $8 trilioni entro il 2030, supportando al contempo i programmi clinici e i costi operativi.
Jupiter Neurosciences (NASDAQ: JUNS) ha anunciado al miembro del Salón de la Fama de la NBA Chris Webber como el segundo embajador de la marca para su línea de suplementos de longevidad Nugevia™. El cinco veces All-Star promoverá los suplementos respaldados por la ciencia de la compañía, basados en la plataforma JOTROL™, un sistema micelar patentado a base de resveratrol.
La línea incluye tres formulaciones — GLO, MND y PWR — diseñadas para potenciar la resiliencia celular mediante ingredientes sinérgicos optimizados para su absorción. Esta iniciativa dirigida al consumidor forma parte de la estrategia dual de Jupiter, que apunta al mercado de la longevidad de $8 billones para 2030, al tiempo que respalda sus programas clínicos y costes operativos.
Jupiter Neurosciences (NASDAQ: JUNS)는 NBA 명예의 전당 멤버 크리스 웨버를 자사의 장수 보충제 라인 Nugevia™의 두 번째 브랜드 홍보대사로 발표했습니다. 5회 올스타 출신 웨버는 특허받은 레스베라트롤 기반 미셀 전달 시스템인 JOTROL™ 플랫폼을 기반으로 한 과학적 근거의 보충제를 홍보합니다.
제품 라인은 흡수 최적화를 통해 시너지 효과를 내는 성분들로 세포 회복력을 높이도록 설계된 GLO, MND, PWR 세 가지 제형으로 구성됩니다. 이 소비자 대상 이니셔티브는 목시플래닛의 임상 개발 프로그램과 운영비를 지원하면서 2030년까지 8조 달러 규모의 장수 시장을 겨냥한 Jupiter의 이중 전략의 일부입니다.
Jupiter Neurosciences (NASDAQ: JUNS) a annoncé l’entrée en tant que deuxième ambassadeur de marque de la légende du NBA et membre du Hall of Fame Chris Webber pour sa gamme de compléments de longévité Nugevia™. Ce quintuple All-Star fera la promotion des compléments scientifiques de la société, basés sur la plateforme JOTROL™, un système micellaire breveté à base de resvératrol.
La ligne comprend trois formulations — GLO, MND et PWR — conçues pour renforcer la résilience cellulaire grâce à des ingrédients synergiques optimisés pour l’absorption. Cette initiative grand public s’inscrit dans la stratégie à double volet de Jupiter, visant le marché de la longévité de 8 000 milliards de dollars d’ici 2030, tout en soutenant ses programmes cliniques et ses coûts opérationnels.
Jupiter Neurosciences (NASDAQ: JUNS) hat den NBA Hall of Famer Chris Webber als zweiten Markenbotschafter für seine Langlebigkeits-Supplementlinie Nugevia™ vorgestellt. Der fünfmalige NBA All-Star wird die wissenschaftlich fundierten Produkte des Unternehmens bewerben, die auf der JOTROL™-Plattform basieren, einem patentierten micellaren Liefersystem auf Resveratrol-Basis.
Die Produktpalette umfasst drei Formulierungen — GLO, MND und PWR — die durch synergistische, für optimale Aufnahme entwickelte Inhaltsstoffe die zelluläre Widerstandsfähigkeit stärken sollen. Diese Verbraucherinitiative ist Teil von Jupiters Doppelstrategie, mit der bis 2030 der 8 Billionen-Dollar-Langlebigkeitsmarkt adressiert sowie klinische Entwicklungsprogramme und Betriebskosten finanziell gestützt werden sollen.
- Strategic partnership with high-profile NBA Hall of Famer Chris Webber enhances brand credibility
- Product line leverages proprietary JOTROL™ technology with proven enhanced bioavailability
- Entry into $8 trillion longevity market creates potential new revenue stream
- Dual-path strategy supports both consumer products and clinical development programs
- Revenue impact and market penetration potential not yet quantified
- Celebrity endorsement costs not disclosed
Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation
Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) today announced that Chris Webber, five-time NBA All-Star and Hall of Fame inductee, has joined the Company as the second official brand ambassador for Nugevia™, Jupiter Neurosciences’ new consumer longevity supplement line.
Webber, who played 15 seasons in the National Basketball Association, including standout years with the Sacramento Kings, brings his championship mindset and commitment to peak performance to the Nugevia mission. Over his career, Webber was named NBA Rookie of the Year, earned five All-NBA selections, and left an indelible mark on the game with his skill, vision, and leadership.
“Chris embodies the principles at the core of Nugevia™: longevity, resilience, and elite performance supported by real science,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “His dedication to preparation and his commitment to excellence both on and off the court make him an ideal advocate for our mission to help people look, feel, and perform their best at every stage of life.”
Webber commented, “In my playing days, staying at the top of my game took more than talent, it took discipline, recovery, and science-backed tools to keep my body and mind sharp. I’m a big believer in putting the right things in your body so you can keep giving your best, year after year. Nugevia’s products aren’t just another supplement, they’re built on real clinical research and cutting-edge technology. Whether you’re competing on the court, running a business, or just trying to keep up with your kids, Nugevia gives you that extra edge to perform at your peak.”
Nugevia™ is built on JOTROL™, Jupiter’s patented resveratrol-based micellar delivery platform that has demonstrated significantly enhanced bioavailability and underpins the Company’s clinical-stage CNS therapies. The three debut formulations—GLO, MND, and PWR—are designed to support cellular resilience through intelligent stacking of synergistic ingredients, all enhanced for optimal absorption via the JOTROL™ system.
The Nugevia™ brand reflects Jupiter’s dual-path strategy, advancing clinically validated therapeutics while tapping into the rapidly growing longevity market, projected to reach
A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease.
In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
IR@jupiterneurosciences.com
Investors:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
Who is the new brand ambassador for Jupiter Neurosciences (JUNS) Nugevia supplements?
What are the three Nugevia supplement formulations from Jupiter Neurosciences?
What is the projected size of the longevity market that JUNS is targeting?
What technology does Jupiter Neurosciences use in their Nugevia supplements?
How does the Nugevia product line fit into Jupiter Neurosciences' business strategy?
